BURNABY, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 9,098,362 common shares, which includes 1,229,508 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 327,868 common shares. The common shares were offered at a public ...
